MEDIPHARM ANDERLECHT
ActiveSummary
The computed 12-month bankruptcy probability of MEDIPHARM ANDERLECHT is 2.1% (moderate). The 2025 annual accounts show equity of €17,978 and a net result of €32,003. Equity remains stable across the filed financial years (±1.8% per year). Its solvency ranks better than 26% of 22,650 sector peers (NACE 47, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.
History
On 29 June 2023, MEDIPHARM ANDERLECHT was incorporated as a private limited company by one natural person, with a starting capital of €3,000.12 CHEAIB Samer has served as director of the company since 2023.2 Total assets went from €278,646 in 2023 to €285,622 in 2025 and headcount from 1 to 2.5 full-time equivalents.3
Acts, filings and financial milestones
03-07
Gazette deed
IncorporationAppointment: CHEAIB Samer (director) · Founder · Founding capital9 facts ▸
- Founder, CHEAIB Samer (comparant)
- Founding capital, €3,000
- Bank account, “BELFIUS, BE34 0689 4924 8390” (deed in French)
- Other provision, “arrêt des statuts, arrêter statuts” (deed in French)
- Capital
- Registered office clause, “1140 Evere, Allées de Provence”, 40 (deed in French)
- Board rule, 1
- Director appointment, CHEAIB Samer (director (not named in the articles))
- Pre-incorporation commitments, “takeover, engagements, obligations et activités au nom et pour compte de société en formation” (deed in French)